Antidoping Control in Brazil: History, Current Situation, and Prospects for the 2014 World Cup and the 2016 Olympic Games

Abstract

Brazil will soon host two major sporting events: the 2014 World Cup and the 2016 Summer Olympic Games. Given the importance of antidoping control during these competitions, it is important that the scientific community receive a status update on antidoping control in Brazil. In this brief communication, the authors present the status of antidoping control in Brazil from an historical perspective, both the benefits and difficulties to be faced by antidoping control during these events, and the legacy resulting from the efficacy of the drug testing performed during these competitions.

Keywords :

• antidoping
• Brazil
• drug testing

THE AUTHORS

Marcos Antonio Pereira dos Santos, Ph.D., has a BA degree in physical education from the Federal University of Piauí (UFPI), with improvement in theory and methodology of sports training from the University of Moscow, Russia, and expertise in physical activity and health from UFPI. His Ph.D. degree is in biotechnology from Northeast Biotechnology Network (RENORBIO). He is currently an Adjunct Professor in the Department of Biophysics and Physiology of UFPI and a member of doping control of the Futbol Brazilian Confederation (CBF). He has experience in the areas of exercise physiology and biophysics, with emphasis on the following topics: sports training, doping in sport, anabolic steroids, sensors, and biosensors.

Alexandre Sérgio Silva, Ph.D., has a BA degree in physical education from the State University of Paraíba. His Ph.D. degree is in Human Motricity Sciences from the State University of São Paulo (UNESP–Rio Claro). He is currently Adjunct Professor at the Federal University of Paraíba (UFPB) and a leader of Physical Training applied to Health and Performance Laboratory (UFPB). His research focuses on the biochemical and metabolic responses to exercise, with emphasis on evaluation of the effectiveness of nutritional ergogenic resources.

Sergio Luiz Galan Ribeiro, Ed.D., has a BA in physical education from the Faculdade de Educação Física de Catanduva–SP. His Ed.D. is in Educational Administration from the University of Georgia, USA, and his master of sciences is from Vanderbilt University, USA. He is currently an Adjunct Professor at the Federal University of Piauí (UFPI). He is Head Chief of the Department of Physical Education at the UFPI and President of the Committee on Sporting Infrastructure of UFPI.

Azenildo Moura Santos, B.A., Ph.D., received his bachelor's degree in physical education and is an exercise Physiology Specialist and Researcher at the Sport Sociology Laboratory, Federal University of Pernambuco (UFPE), Brazil. In addition, Santos has authored several chapters on health and physical education. He completed his Ph.D. in Public Health, with an ethnographic approach, at the Public Health Institute (ISC), Federal University of Bahia (UFBA), Salvador, Brazil, where he was awarded a scholarship as a research fellow at the National Council of Scientific and Technologic Development (CNPq), Ministry of Science and Technology, Brazil. Santos was also awarded a scholarship as a research fellow from Coordination for the Improvement of Higher Education Personnel (CAPES), Ministry of Education, Brazil, to conduct research in the Sociology Department, at Goldsmiths University of London, United Kingdom. The author's primary research interests include performance-enhancing substances, doping in sport and exercise, body image in sports and exercise, sport sociology, sports nutrition, anabolic-androgenic steroids in public health, health promotion, and badminton.

Notes

2 The LADETEC received negative marks for incorrect tests and an error in a double-blind test. Experts say that the delay in release of funds for the purchase of reagents and equipment was also a cause of difficulty for the LADETEC. Bureaucracy may have also been a cause due to delays in clearance by customs and the release of urine samples, which are considered an import. This release is approved by the ANVISA (Lucchetti, 2013).